Scientists from Rutgers University and the University of Pennsylvania have identified a biological pathway that could explain why current asthma therapies often prove ineffective.
The discovery has the potential to lead to new treatments for many of the 25 million people in the U.S., including seven million children, who suffer from the chronic condition.
Researchers Reynold A. Panettieri, inaugural director of the clinical and translational science institute at Rutgers, and Edward E. Morrissey, director of the Penn Center for Pulmonary Biology, determined that when certain genes in mice were inactivated, the mice developed an asthma-like condition, exhibiting airway hyper-responsiveness, or AHR, a classic sign of asthma.